STAT3 inhibitors are effective in bladder cancer as a single agent55 and in combination with chemotherapeutic agents and oncolytic virotherapy56; future studies can investigate whether STAT 3 inhibitors target IL‐17‐producing hILC1s in bladder cancer. Here, IL17A is linked to urinary bladder carcinoma.